The present snack-type food product with high hypoproteic content comprises proteins of high biological value (HBV), in which the principal macronutrients are protein, sugars, carbohydrates and fats. This snack-type food product was specifically developed for patients undergoing haemodialysis treatment. The snack-type food product has sensory characteristics that allow it to achieve better acceptance in comparison with other products available on the market.

The present snack-type food product with high hypoproteic content comprises proteins of high biological value (HBV), in which the principal macronutrients are protein, sugars, carbohydrates and fats. This snack-type food product was specifically developed for patients undergoing haemodialysis treatment. The snack-type food product has sensory characteristics that allow it to achieve better acceptance in comparison with other products available on the market.

The present disclosure relates to a cocrystal of pterostilbene and a coformer capable to form hydrogen bond interactions, to a process for the preparation thereof, and to its use as a medicament or a dietary supplement. The present disclosure also relates to a composition comprising the cocrystal.

The present disclosure provides a feed additive for domesticated animals that is capable of increasing feed performance, as well as associated methods for promoting growth and zootechnical performance in domesticated animals. The animal feed additive provided contains Total Lignans standardized in the contents of Furoguaiacin-like compounds and Guaiacin-like compounds. The present disclosure also describes methods for improving growth via the dietary inclusion of Total Lignans standardized in Furoguaiacin-like compounds and Guaiacin-like compounds.

The present disclosure provides a feed additive for domesticated animals that is capable of increasing feed performance, as well as associated methods for promoting growth and zootechnical performance in domesticated animals. The animal feed additive provided contains Total Lignans standardized in the contents of Furoguaiacin-like compounds and Guaiacin-like compounds. The present disclosure also describes methods for improving growth via the dietary inclusion of Total Lignans standardized in Furoguaiacin-like compounds and Guaiacin-like compounds.

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.

The present invention provides a solid composition containing an amorphous poorly water-soluble material, and a method for producing the same. The solid composition of the present invention is a solid composition containing an amorphous poorly water-soluble material (1a), hydroxypropylmethyl cellulose (2), and one or more types of water-soluble polysaccharides (3) other than hydroxypropylmethyl cellulose, and is characterized in that an XRD analysis value of the solid composition is 4.0% or less.

The present invention aims to provide a highly safe composition that can be used for improving or maintaining mitochondrial function and/or mitochondrial energy production capacity or reducing a decline in mitochondrial function and/or mitochondrial energy production capacity and that allows easy intake and continuous ingestion without risk of side effects. The present invention also aims to provide, for example a method of improving or maintaining mitochondrial function and/or mitochondrial energy production capacity or reducing a decline in mitochondrial function and/or mitochondrial energy production capacity. The present invention relates to, for example, a composition containing at least one sesamin-class compound and pyrroloquinoline quinone (PQQ) or a salt thereof.

The present invention discloses a nutraceutical composition for up-regulation of SIRT 1 expression. The nutraceutical composition comprises NMN at in an amount between 300 mg and 500 mg, in an amount of 500 mg, and a soluble agent. The NMN and polyphenol are wrapped in a soluble agent as a protective bio-active agent to increase bioavailability and protect the polyphenol compounds during gut absorption. The invention also discloses a method of preparing a nutraceutical composition by weighing polyphenol at a suitable concentration, mixing the polyphenol with a suitable soluble agent and finally adding NMN to the mixture and blended it to form the nutraceutical composition. The nutraceutical composition up regulates SIRT1 and hence is suitable for treatment of various diseases and used in the form of powder, liquid, tablets, capsules, chewable form, gels, etc.